Rituximab for the treatment of acute exacerbation of interstitial lung disease associated with connective tissue disease
Background Acute exacerbation of interstitial lung disease (AE-ILD) is a severe complication with a poor prognosis. No clinical trials have supported the use of rituximab in AE-ILD associated with connective tissue disease.Methods We present a series of four cases in which administration of rituxima...
Main Authors: | Francisco León Román, Beatriz Pintado-Cort, Diana García-Casado, Francisco Muñiz-González, José Antonio López García-Asenjo, Cristina Díaz-Rodríguez, María Nieves Montoro-López, Mauricio Loucel-Bellino, Beatriz Recio-Moreno, Sara Rebollo-Garrido, Yaiza Martínez-Hernández, Ivan Cusacovich |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-08-01
|
Series: | RMD Open |
Online Access: | https://rmdopen.bmj.com/content/9/3/e003479.full |
Similar Items
-
Interstitial lung disease in patients with scleroderma - Treatment with rituximab
by: Marenco J L, et al.
Published: (2010-11-01) -
Rituximab treatment in patients with systemic sclerosis and interstitial lung disease
by: Abdel Gaffar A Mohammed, et al.
Published: (2017-01-01) -
A rare case of rituximab induced interstitial lung disease
by: Kamal Kant Sahu, et al.
Published: (2016-01-01) -
Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease
by: Caterina Vacchi, et al.
Published: (2021-01-01) -
Efficacy and Safety of Rituximab in Autoimmune Disease—Associated Interstitial Lung Disease: A Prospective Cohort Study
by: Natalia Mena-Vázquez, et al.
Published: (2022-02-01)